In clinical trials, CAR T cell immunotherapy continues to yield complete responses in children and young adults with relapsed and refractory leukemia. A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children’s Hospital of Philadelphia (CHOP) reported new results using T cell…